Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for Tourette Syndrome
Reason given: Inability to recruit participants
Key facts
- Phase
- Phase 1
Trial details
- Who runs it
- The Foundation for Orthopaedics and Regenerative Medicine
- Trial code
- NCT05158439
- Record updated
- 16 October 2026
- Original description
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Tourette SyndromeRead full original descriptionShow less
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Tourette Syndrome
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Tourette Syndrome
Inclusion: Diagnosis of Tourette Syndrome; Understanding and willingness to sign a written informed consent document.
Exclusion: Continued drug abuse; Previous organ transplant; Active infection; Active cancer; Chronic multisystem organ failure; Medical condition that would (based on the opinion of the investigator) compromise patient's safety; Hypersensitivity to sulfur; Clinically significant Abnormalities on pre-treatment laboratory evaluation; Pregnancy; Pre-menopausal women not using contraception.